<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Talc (sterile): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Talc (sterile): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Talc (sterile): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12130" href="/d/html/12130.html" rel="external">see "Talc (sterile): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F6021564"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Sclerosol Intrapleural;</li>
<li>Sterile Talc Powder;</li>
<li>Steritalc</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F6021566"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Sclerosing Agent</li></ul></div>
<div class="block doa drugH1Div" id="F6021773"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="56e5465a-1ac1-4d69-bbad-53bff28779bc">Pleural effusion, malignant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pleural effusion, malignant:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Aerosol: <b>Intrapleural: </b>4 to 8 g (1 to 2 cans) as a single dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Suspension:</p>
<p style="text-indent:-2em;margin-left:6em;">Sterile Talc Powder: <b>Intrapleural:</b> 5 g as a single dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Steritalc: <b>Intrapleural:</b> 2 to 5 g as a single dose (based on patient diagnosis and condition other doses may be used); maximum cumulative dose: 10 g.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="854558f6-0637-4484-ac53-e6c8bf1d158d">Pneumothorax</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumothorax: </b>Steritalc: <b>Intrapleural:</b> 2 g as a single dose (based on patient diagnosis and condition other doses may be used); maximum cumulative dose: 10 g.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50992044"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;">There are no dosage adjustments provided in the manufacturer's labeling. </p></div>
<div class="block doha drugH1Div" id="F50989287"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;">There are no dosage adjustments provided in the manufacturer's labeling. </p></div>
<div class="block doe drugH1Div" id="F56835060"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F247653"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, cardiac arrhythmia, hypotension, pulmonary embolism, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypovolemia</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Pain</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Acute respiratory distress syndrome, bronchopleural fistula, dyspnea, empyema of pleura, hemoptysis, pneumonia, pneumonitis (including interstitial pneumonitis) (Griffo 2009), respiratory failure (Griffo 2009)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F6021570"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Steritalc:</b> Pregnancy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Sclerosol, Sterile Talc Powder:</b> There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F6021571"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary effects: Acute pneumonitis and acute respiratory distress syndrome (ARDS), including fatalities have been reported with intrapleural sterile talc; most cases of ARDS occurred with talc doses of 10 g via a chest tube. Systemic sterile talc exposure may be affected by the visceral pleura integrity and may be increased if sterile talc is administered following mechanical pleura abrasion or biopsy. Talc particle size distribution may correlate with the risk of toxicities. Products are for intrapleural use only; IV administration (not recommended) is associated with pulmonary hypertension and lung parenchymal disease. Silicosis or asbestosis-like conditions (chronic bronchitis, bronchogenic carcinoma, and pleural plaques) are associated with inhaled talc.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Sclerosol: Contents under pressure and should be kept away from any heat source or open flame; do not puncture canister.</p>
<p style="text-indent:-2em;margin-left:4em;">• Steritalc: Lead exposure: Steritalc contains lead (as an impurity). The primary target organ for lead toxicity is the central nervous system, although lead exposure may also have an impact on blood pressure, renal function, and anemia. The threshold for minimum risk exposure levels has not been fully established in humans. Pediatric patients are more sensitive to lead toxicity (than adults); a safe blood level has not been established in children. Cognitive and neurobehavioral deficits are observed in children exposed to lead.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Should not be used for potentially curable malignancies where systemic therapy would be more appropriate (sterile talc does not have antineoplastic activity). Clinicians should evaluate need for future diagnostic or surgical procedures before use; sclerosis of pleural space may preclude or complicate subsequent ipsilateral surgery and diagnostic procedures (eg, pneumonectomy for transplantation).</p></div>
<div class="block foc drugH1Div" id="F247656"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Aerosol Powder, Intrapleural: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sclerosol Intrapleural: 4 g (30 g) [contains dichlorodifluoromethane]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Powder, Intrapleural: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Steritalc: 2 g (1 ea); 3 g (1 ea); 4 g (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted, Intrapleural: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sterile Talc Powder: 5 g (1 ea)</p></div>
<div class="block geq drugH1Div" id="F20452410"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16323637"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Aerosol powder</b> (Sclerosol Intrapleural Intrapleural)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 g (per gram): $4.20</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Powder</b> (Steritalc Intrapleural)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 g (per each): $142.50</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3 g (per each): $183.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 g (per each): $204.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension (reconstituted)</b> (Sterile Talc Powder Intrapleural)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 g (per each): $97.50</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F6021774"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">For intrapleural (pleurodesis) administration only; <b>not for IV administration</b>. Administer after adequate drainage of the effusion or air.</p>
<p style="text-indent:-2em;margin-left:2em;">Sclerosol Intrapleural Aerosol: Shake well and attach delivery tube. Insert delivery tube through pleural trocar, manually press on actuator button of canister to release; point in several different directions to distribute to all pleural surfaces. Keep canister in an upright position for optimal distribution. Rate of delivery is 1.2 g per second.</p>
<p style="text-indent:-2em;margin-left:2em;">Sterile Talc Powder: Administer as a suspension. Shake well before instillation. Vent the10 mL air headspace and empty contents of each syringe into chest cavity through the chest tube by gently applying pressure to syringe plunger. After administration, clamp the chest tube for 1 to 2 hours and then drain the pleural fluid; the chest tube can be removed when drainage is &lt;100 to 150 mL/24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15764775','lexi-content-ref-17873181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15764775','lexi-content-ref-17873181'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Steritalc:</p>
<p style="text-indent:-2em;margin-left:4em;">Slurry for tube thoracostomy: Shake syringe well prior to administration to redisperse talc and avoid settling. Immediately prior to administration, vent the 10 mL air headspace from each syringe and administer talc suspension through the chest tube (follow standard procedures). Inject slurry through pleural drainage into pleural cavity; clamp pleural drainage and retain negative pressure in the pleural cavity. With slurry in cavity, re-position patient regularly to achieve even slurry distribution. Aspirate slurry through pleural drainage.</p>
<p style="text-indent:-2em;margin-left:4em;">Insufflation/poudrage: Perform procedure with a tube thoracoscopy. Follow device instructions for insufflation or poudrage. After use, some talc may remain in the vial (discard unused portion).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>2 or 4 g vials:</i> Introduce cannula into trocar, distribute talc evenly in pleural cavity by spraying several times and changing cannula direction every few sprays.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>3 g vial:</i> Keep product upright during use; avoid contact between the cannula tip and tissue or body fluids (may result in blocked cannula; if blockage occurs, shorten cannula with a scalpel, cutting perpendicular to cannula and ensuring the cut edge is straight and smooth). Proceed with intervention by introducing cannula into the trocar, distribute the talc evenly in the pleural cavity by pressing insufflation bulb carefully and at regular intervals. After spraying a few times, change the cannula direction.</p></div>
<div class="block use drugH1Div" id="F247657"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Pleural effusion, malignant:</b> Sclerosing agent to decrease or prevent the recurrence of malignant pleural effusion in symptomatic patients (following maximal drainage of pleural effusion).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumothorax:</b> Sclerosing agent to decrease the recurrence of pneumothorax.</p></div>
<div class="block mst drugH1Div" id="F56413152"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block rep_considerations drugH1Div" id="F53145039"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Patients who could become pregnant should use effective contraception during Steritalc treatment and for 5 months following the final dose. Steritalc may impair fertility in males (decreased sperm production).</p></div>
<div class="block pri drugH1Div" id="F6021568"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Steritalc is contraindicated in pregnancy; Steritalc contains lead (as an impurity); lead exposure during pregnancy may result in miscarriage, premature birth, low birth weights, and slow/impaired mental childhood development. When used at the highest recommended dose (10 grams), Steritalc may deliver ≤40 mcg of lead.</p>
<p style="text-indent:0em;margin-top:2em;">Pneumothorax during pregnancy is rare; however, pregnancy and the birth process may increase the risk. The individual risks of various treatments to the mother and fetus should be considered in consultation with a multidisciplinary health care team (MacDuff 2010; Schnell 2019).</p></div>
<div class="block brc drugH1Div" id="F25316061"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if sterile talc is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Steritalc contains lead (as an impurity), which is known to have an adverse effect on health and development in neonates, infants, and children. Due to the potential for serious adverse reactions resulting from lead exposure in the breastfed infant, lactating patients should avoid breastfeeding during Steritalc treatment and for 5 months following the final dose.</p></div>
<div class="block pha drugH1Div" id="F6021771"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Sterile talc instilled into the pleural cavity induces an inflammatory reaction, promoting adherence of the visceral and parietal pleura, therefore, preventing reaccumulation of pleural air or fluid.</p></div>
<div class="block phk drugH1Div" id="F25316083"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Absorption: Not well studied; systemic exposure may be influenced by integrity of visceral pleura</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-15764775">
<a name="15764775"></a>Dresler CM, Olak J, Herndon JE, et al, “Phase III Intergroup Study of Talc Poudrage Vs Talc Slurry Sclerosis for Malignant Pleural Effusion,” <i>Chest</i>, 2005, 127(3):909-15.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/talc-sterile-drug-information/abstract-text/15764775/pubmed" id="15764775" target="_blank">15764775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19157360">
<a name="19157360"></a>Griffo S, Musumeci A, De Luca G, Saccenti A, Grande LM, Stassano P. Talc-induced interstitial pneumonitis with respiratory failure. <i>Anaesth Intensive Care</i>. 2009;37(1):127-129. doi:10.1177/0310057X0903700114<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/talc-sterile-drug-information/abstract-text/19157360/pubmed" id="19157360" target="_blank">19157360</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17873181">
<a name="17873181"></a>Kvale PA, Seleecky PA, and Prakash UB, “Palliative Care in Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition),” <i>Chest</i>, 2007, 132(3 Suppl):368-403.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/talc-sterile-drug-information/abstract-text/17873181/pubmed" id="17873181" target="_blank">17873181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20696690">
<a name="20696690"></a>MacDuff A, Arnold A, Harvey J; BTS Pleural Disease Guideline Group. Management of spontaneous pneumothorax: British Thoracic Society pleural disease guideline 2010. <i>Thorax</i>. 2010;65(suppl 2):ii18-31. doi: 10.1136/thx.2010.136986.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/talc-sterile-drug-information/abstract-text/20696690/pubmed" id="20696690" target="_blank">20696690</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30041191">
<a name="30041191"></a>Schnell J, Beer M, Eggeling S, et al. Management of spontaneous pneumothorax and post-interventional pneumothorax: German S3 guideline. <i>Respiration</i>. 2019;97(4):370-402. doi: 10.1159/000490179.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/talc-sterile-drug-information/abstract-text/30041191/pubmed" id="30041191" target="_blank">30041191</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Sclerosol intrapleural aerosol (sterile talc) [prescribing information]. Woburn, MA: Bryan Corporation; October 2012.</div>
</li>
<li>
<div class="reference">
                  Sterile Talc Powder (sterile talc powder) [prescribing information]. Woburn, MA: Bryan Corporation; June 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Steritalc.1">
<a name="Steritalc.1"></a>Steritalc (sterile talc powder) [prescribing information]. La Ciotat Cedex, France: Novatech SA; received January 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9496 Version 105.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
